Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/02/07/2825233/0/en/LAPIX-Therapeutics-Strengthens-Board-of-Directors-with-Appointments-of-Pharmaceutical-Industry-Veterans-Henry-A-McKinnell-Ph-D-Anthony-Gibney-and-Francisco-Leon-MD-Ph-D.html
https://www.globenewswire.com//news-release/2023/11/07/2775104/0/en/LAPIX-Therapeutics-Inc-Announces-First-Subjects-Dosed-in-its-First-in-Human-Clinical-Study-of-its-Treg-expanding-Tim3-4-Agonist-LPX-TI641-to-Treat-Multiple-Sclerosis-and-other-Auto.html
https://www.globenewswire.com//news-release/2023/09/18/2744820/0/en/LAPIX-Therapeutics-Inc-Announces-FDA-Clearance-of-IND-Application-for-its-Treg-expanding-Tim3-4-Agonist-LPX-TI641-to-Treat-Multiple-Sclerosis.html
https://www.globenewswire.com/news-release/2023/05/17/2671058/0/en/LAPIX-Therapeutics-Inc-Announces-the-Issuance-of-U-S-Patent-for-LPX-TI641-Its-First-in-Class-Orally-Administered-Tim3-4-Agonist-for-Treg-Expansion-to-Treat-Autoimmune-Diseases.html
https://www.globenewswire.com/news-release/2023/01/26/2596120/0/en/LAPIX-Therapeutics-Inc-Announces-a-Successful-Conclusion-of-its-Pre-IND-Meeting-Request-with-the-U-S-FDA.html